Associated Papers
Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis.
Houlahan KE et al.
Ebiomedicine, 2026
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.
Zwimpfer TA et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Deletions Rate-Limit Breast and Ovarian Cancer Initiation.
Houlahan KE et al.
Biorxiv : the Preprint Server for Biology, 2024
Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.
Qin Z et al.
International Journal of Cancer, 2023
The highest frequency of BRCA1 c.3700_3704del detected among Albanians from Kosovo.
Kostovska IM et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2022
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy.
Figlioli G et al.
Cancers, 2021
The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries.
Laitman Y et al.
Human Mutation, 2019
Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
Bhaskaran SP et al.
International Journal of Cancer, 2019
BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
Jakimovska M et al.
Breast Cancer Research and Treatment, 2018
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.
Walker LC et al.
European Journal of Human Genetics : Ejhg, 2017
BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer.
Sambiasi D et al.
Oncology Reports, 2014
Genetic variation of the brca1 and brca2 genes in macedonian patients.
Maleva I et al.
Balkan Journal of Medical Genetics : Bjmg, 2012
Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.
Judkins T et al.
Cancer Research, 2005